Our core content on Lung conditions and related factsheets has been translated to a number of other languages.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
Our core content on Lung conditions and related factsheets has been translated to a number of other languages by our volunteer team.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
Home » Study sheds light on how lung cancer spreads in the early stages
A summary of research published in Nature
A new study has revealed some of the processes that happen in the body in the early stages of lung cancer. The research, published in the journal Nature, offers some hope that new drugs could be developed to target this process and slow down or prevent the growth of lung cancer tumours.
Researchers took lung tissue samples and lung tumour samples from 35 people who had surgery to remove parts of the lung with cancer. The researchers then analysed these samples and blood samples from each person in a laboratory. The researchers looked at the lung tissue around the tumour. They did this to understand what happens to the body’s cells as lung cancer takes hold.
By studying the cells in the samples, the researchers could map out a surprising process happening as the tumours grew in the lungs. Immune cells, which normally repair tissue in the body, were being used by tumours when cancer started to grow in the lung. The tumours were able to ‘trick’ the cells into helping them to invade the lung. The process helped tumours to hide from the immune system, that would usually defend the body against disease. The cancer was then able to progress to later stages.
Lung cancer is often diagnosed at a late stage and research efforts have focused on understanding the early stages of lung cancer in the hope of identifying new target areas for treatments. This study helps to build up a picture of what happens in the lung as cancer grows and then spreads. By exploring this, researchers hope that they can understand what drives tumour growth. The processes they discover can then be used as target areas for treatments, such as immunotherapy, which works by supporting our body’s immune system to fight cancer.
Title: Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells
Sign up to our free monthly newsletter to get the latest information and research news on lung conditions, plus views from experts and patients! You can unsubscribe at any time.
ELF is a non-profit organisation registered as a UK company (VAT no. GB 115 0027 74) and charity (no. 1118930).
Our Brussels office enterprise number is 0738.383.695
European Lung Foundation's TR ID number in the Transparency Register is: 094039644810-79